Download PDF
TumorDiagnostik & Therapie 2019; 40(07): 429-432
DOI: 10.1055/a-0918-3328
Schwerpunkt Mammakarzinom
© Georg Thieme Verlag KG Stuttgart · New York

Tumor- und stadienspezifische Therapie des Mammakarzinoms

Michael Eichbaum
Further Information

Publication History

Publication Date:
30 August 2019 (online)

Also available at
    Permissions and Reprints

Für das Mammakarzinom konnten in den vergangenen Jahren aufgrund des stetig wachsenden Wissens über die Biologie der Tumoren die Therapieansätze immer weiter differenziert und personalisiert werden. Derzeit werden auch Checkpoint-Inhibitoren klinisch getestet, und die ersten Ergebnisse sind vielversprechend.
 

  • Literatur

  • 1 Houssami N. et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 2010; 46: 3219-3232
    CrossrefPubMedGoogle Scholar
  • 2 Giuliano AE. et al. Effect of Axillary Dissection vs no Axillary Dissection on 10-Year Overall Survival AmongWomen With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017; 318: 918-926
    CrossrefPubMedGoogle Scholar
  • 3 Reimer T. et al. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd 2017; 77: 149-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Leitlinienprogramm Onkologie. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 4.1, September 2018, AWMF-Registernummer: 032-0450L.
    PubMedGoogle Scholar
  • 5 Sparano JA. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121
    CrossrefPubMedGoogle Scholar
  • 6 von Minckwitz G. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
    CrossrefPubMedGoogle Scholar
  • 7 Hosford SR. et al. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014; 7: 203-215
    CrossrefPubMedGoogle Scholar
  • 8 Cardoso F. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer. Ann Oncol 2017; 28: 16-33
    CrossrefPubMedGoogle Scholar
  • 9 Schmid P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
    CrossrefPubMedGoogle Scholar
  • 10 Li MM. et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Molec Diagn 2017; 19: 4-23
    PubMedGoogle Scholar